$1.26
-0.02-1.56%
At close: -
$1.25
-0.01-0.79%
After Hours: 6:41 PM EDT
Comments
Loading...
AN2 Therapeutics Analyst Ratings and Price Targets | NASDAQ:ANTX | Benzinga
AN2 Therapeutics Inc has a consensus price target of $11.8 based on the ratings of 9 analysts. The high is $25 issued by SVB Leerink on November 14, 2022. The low is $2 issued by Evercore ISI Group on May 16, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, Citizens Capital Markets, and JMP Securities on March 26, 2025, February 25, 2025, and February 3, 2025, respectively. With an average price target of $5 between Citizens Capital Markets, Citizens Capital Markets, and JMP Securities, there's an implied 300.00% upside for AN2 Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citizens Capital Markets
JMP Securities
Evercore ISI Group
SVB Leerink
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for AN2 Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/26/2025 | Buy Now | 300% | Citizens Capital Markets | Roy Buchanan34% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/25/2025 | Buy Now | 300% | Citizens Capital Markets | Roy Buchanan34% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/03/2025 | Buy Now | 300% | JMP Securities | Roy Buchanan34% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/19/2024 | Buy Now | 300% | JMP Securities | Roy Buchanan34% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | — | TD Cowen | Ritu Baral35% | — | Downgrade | Buy → Hold | Get Alert |
| 08/09/2024 | Buy Now | 140% | JMP Securities | Roy Buchanan34% | $6 → $3 | Maintains | Market Outperform | Get Alert |
| 07/03/2024 | Buy Now | — | Leerink Partners | Joseph Schwartz64% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | 60% | Evercore ISI Group | Liisa Bayko69% | $7 → $2 | Maintains | In-Line | Get Alert |
| 04/02/2024 | Buy Now | 380% | JMP Securities | Roy Buchanan34% | → $6 | Upgrade | Market Perform → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | — | Oppenheimer | Jeff Jones32% | — | Reiterates | Perform → Perform | Get Alert |
| 02/13/2024 | Buy Now | 460% | Leerink Partners | Joseph Schwartz64% | $23 → $7 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/12/2024 | Buy Now | 460% | Evercore ISI Group | Liisa Bayko69% | $25 → $7 | Downgrade | Outperform → In-Line | Get Alert |
| 02/12/2024 | Buy Now | — | Oppenheimer | Jeff Jones32% | — | Downgrade | Outperform → Perform | Get Alert |
| 02/12/2024 | Buy Now | — | JMP Securities | Roy Buchanan34% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 01/04/2024 | Buy Now | 2300% | JMP Securities | Roy Buchanan34% | → $30 | Initiates | → Market Outperform | Get Alert |
| 03/30/2023 | Buy Now | 1820% | Oppenheimer | Jeff Jones32% | $20 → $24 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 1900% | SVB Leerink | Joseph Schwartz64% | $27 → $25 | Maintains | Outperform | Get Alert |
| 04/19/2022 | Buy Now | 1900% | Evercore ISI Group | Liisa Bayko69% | → $25 | Initiates | → Outperform | Get Alert |
| 04/19/2022 | Buy Now | 1660% | Oppenheimer | Kevin DeGeeter65% | → $22 | Initiates | → Outperform | Get Alert |
| 04/19/2022 | Buy Now | — | Cowen & Co. | Ritu Baral35% | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for AN2 Therapeutics (ANTX) stock?
The latest price target for AN2 Therapeutics (NASDAQ:ANTX) was reported by Citizens Capital Markets on March 26, 2025. The analyst firm set a price target for $5.00 expecting ANTX to rise to within 12 months (a possible 300.00% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AN2 Therapeutics (ANTX)?
The latest analyst rating for AN2 Therapeutics (NASDAQ:ANTX) was provided by Citizens Capital Markets, and AN2 Therapeutics reiterated their market outperform rating.
When was the last upgrade for AN2 Therapeutics (ANTX)?
The last upgrade for AN2 Therapeutics Inc happened on July 3, 2024 when Leerink Partners raised their price target to N/A. Leerink Partners previously had a market perform for AN2 Therapeutics Inc.
When was the last downgrade for AN2 Therapeutics (ANTX)?
The last downgrade for AN2 Therapeutics Inc happened on November 18, 2024 when TD Cowen changed their price target from N/A to N/A for AN2 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for AN2 Therapeutics (ANTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AN2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AN2 Therapeutics was filed on March 26, 2025 so you should expect the next rating to be made available sometime around March 26, 2026.
Is the Analyst Rating AN2 Therapeutics (ANTX) correct?
While ratings are subjective and will change, the latest AN2 Therapeutics (ANTX) rating was a reiterated with a price target of $5.00 to $5.00. The current price AN2 Therapeutics (ANTX) is trading at is $1.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
